Biotech News
PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 Announced closing of oversubscribed $50 million public offering of securities Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash
